Navigation Links
Palatin Technologies Receives Non-Compliance Letter from NYSE Amex
Date:12/2/2010

of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about meeting continued listing standards, plans of compliance relating to regaining compliance with listing standards, future financings and other future expectations of Palatin Technologies, Inc., are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, availability of financing on acceptable terms, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, com
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
5. Palatin Technologies to Present at 8th Annual BIO Investor Forum
6. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
7. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
10. Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
11. Palatin Technologies to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... Aug. 10, 2011 GNS Healthcare, Inc., (GNS) ... personalized medicine to improve human health, today announced ... Bristol-Myers Squibb Company (NYSE: BMY ) ... and biomarkers in the area of immuno-inflammation.  Utilizing ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) announced today ... will present at the Wedbush Securities 2011 Life Sciences Management ... on Tuesday, August 16, 2011. This presentation ... Relations section of Ardea,s website at www.ardeabio.com . Please ...
Cached Medicine Technology:GNS Healthcare Announces Collaboration With Bristol-Myers Squibb 2Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference 2
(Date:8/29/2014)... of clinical trials based on administering antidepressants for ... that more trials are needed to determine whether ... on a regular basis., Dr. Ian Gilron, a ... the Department of Anesthesiology, and his team of ... the use of antidepressants for pain relief post-surgery ...
(Date:8/29/2014)... 2, 2014) A team of scientists from the ... breakthrough discovery of a process to expand production of ... could have implications that extend beyond cancer, including treatments ... In an article published Aug. 29 in ... Gates Center for Regenerative Medicine and Stem Cell Biology ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... new study from the research group of Dr. John Lewis ... Health Research Institute (London, ON) has confirmed that "invadopodia" play ... published in Cell Reports , shows preventing these tentacle-like ... , Roughly 2 in 5 Canadians will develop cancer ... die of the disease. In 2014, it,s estimated that nine ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Top10inaction, a ... web conference providers in the online service industry for ... were global leaders Webex, GotoMeeting and Infinite. , With ... users have to determine which provider is ideally a ... conference businesses search for compelling consumer goods and services ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... of Medicine (BUSM), Management (SMG) and Law (LAW), along ... that public-sector research has had a more immediate effect ... findings, which appear as a Special Article in the ... of Medicine , have economic and policy implications. ...
... HealthDay Reporter , WEDNESDAY, Feb. 9 (HealthDay ... cell genome revealed never-before-seen changes in DNA that may ... mapping the full genetic blueprint of the tumor, researchers ... of more targeted drugs and a better understanding of ...
... investing in public parks and recreation sites may be ... healthcare system, according to Penn State researchers. Investments in ... health and fitness, say Geof Godbey, professor emeritus of ... and parks management. "There is a strong relationship between ...
... heart disease, cancers, HIV and other diseases quickly and ... microsponges are an essential component of Rice University,s Programmable ... in the journal Small . The ... and Chemistry, and his colleagues at Rice,s BioScience Research ...
... Family Physicians demonstrates that vulvar cancer occurs most frequently in women ... with vulvar cancer are age 70 or older, and the rate ... by 75 years of age. , A team of researchers headed ... in Women,s Oncology at Women & Infants Hospital of Rhode Island, ...
... Poor memory and problems with other mental skills may be early ... Researchers gave a word recall memory test to 17,851 people, ... measure the brain,s executive functioning skills. The participants, who were aged ... stroke, were then contacted twice a year for up to 4.5 ...
Cached Medicine News:Health News:Researchers find public sector research responsible for many new drug discoveries 2Health News:Researchers find public sector research responsible for many new drug discoveries 3Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:Key to better health care may be a walk in the park 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:Researchers: Elderly patients 4 times more likely to die from treatment complications 2Health News:Could Poor Memory Signal Raised Stroke Risk? 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: